home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650511.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
3KB
|
46 lines
Document 0511
DOCN M9650511
TI Cell cycle inhibition of HTLV-I transformed T cell lines by retinoic
acid: the possible therapeutic use of thioredoxin reductase inhibitors.
DT 9605
AU U-Taniguchi Y; Furuke K; Masutani H; Nakamura H; Yodoi J; Institute for
Virus Research, Kyoto University, Japan.
SO Oncol Res. 1995;7(3-4):183-9. Unique Identifier : AIDSLINE MED/96170919
AB Adult T cell leukemia derived factor (ADF), which was first reported as
a cytokine-like factor produced by human T lymphotropic virus I
(HTLV-I)-transformed T cells, is a human homologue of thioredoxin (TRX).
ADF/TRX has multiple functions including growth promoting, antiapoptotic
and radical scavenging activities, and is also involved in a wide
variety of intracellular processes as a dithiol reducing agent in
cooperation with the NADPH-TRX reductase system. In HTLV-1(+) T cell
lines, HuT 102 and MT-2, which are ADF/TRX high producing cells, we
found that the expression of ADF/TRX was dependent on the cell cycle and
peaked at S phase. The reducing activity of ADF/TRX in these cells was
also dependent on the cell cycle and elevated in S phase as determined
by NADPH-dependent insulin degradation assay. Furthermore, inhibitors of
TRX reductase, 13-cis-retinoic acid (13-cis-RA) and azelaic acid,
inhibited the DNA synthesis of these cells. In contrast, the residual
expression and reducing activity of ADF/TRX in HTLV-I(-) T cell lines
did not show any significant correlation with the cell cycle. There was
no distinct inhibitory effect of 13-cis-RA or azelaic acid on the growth
of these ADF/TRX low producing cells. These results indicate that a high
level of reducing activity of the ADF/TRX system may be required for the
cell division of these virally transformed cells. This suggests that the
TRX reductase inhibitors including retinoid derivatives have a potential
therapeutic utility for treatment of HTLV-1(+) T cell leukemia without
any effect on HTLV-I(-) cells.
DE Cell Cycle/DRUG EFFECTS Cell Division/DRUG EFFECTS Cell Line,
Transformed *Cell Transformation, Viral Comparative Study
Cytokines/METABOLISM Dicarboxylic Acids/PHARMACOLOGY Enzyme
Inhibitors/*PHARMACOLOGY/THERAPEUTIC USE Growth Substances/METABOLISM
Human HTLV-I/*PHYSIOLOGY Insulin/METABOLISM Neoplasm
Proteins/METABOLISM Support, Non-U.S. Gov't
T-Lymphocytes/CYTOLOGY/DRUG EFFECTS/*VIROLOGY Thioredoxin/METABOLISM
Thioredoxin Reductase (NADPH)/*ANTAGONISTS & INHIB/METABOLISM
Tretinoin/*PHARMACOLOGY Tumor Cells, Cultured Vitamin K/PHARMACOLOGY
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).